Jade Biosciences filings document a Nasdaq-listed clinical-stage biotechnology issuer developing antibody therapies for autoimmune diseases. Form 8-K reports furnish operating and financial results and attach corporate updates covering JADE101, JADE201, JADE301, research progress, and liquidity-related disclosures.
The company's proxy and material-event filings cover annual meeting matters, board and officer changes, compensatory arrangements, employment inducement stock plans, material agreements, private placement securities, common stock and pre-funded warrant terms, and other capital-structure disclosures. The filings also identify Jade as an emerging growth company with common stock registered under the Exchange Act.
Jade Biosciences, Inc. entered into an underwriting agreement for a public offering of 10,000,000 shares of common stock at $15.00 per share, with underwriters purchasing at $14.10 per share. Jade expects gross proceeds of $150.0 million and net proceeds of approximately $140.3 million.
The company granted underwriters a 30-day option to buy up to an additional 1,500,000 shares at the public price, which would raise expected net proceeds to about $161.5 million if exercised in full. The offering, conducted under an effective Form S-3 shelf registration, is expected to close on June 5, 2026, and Jade plans to use net proceeds to fund clinical and preclinical programs, manufacturing, R&D, capital spending, working capital and general corporate purposes.
Jade Biosciences is offering 10,000,000 shares of its common stock at $15.00 per share in a registered primary offering. The prospectus supplement states gross proceeds of $150,000,000, underwriting discounts of $9,000,000 and estimated net proceeds to the company of approximately $140.3 million (or approximately $161.5 million if the underwriters fully exercise a 30-day option to purchase an additional 1,500,000 shares). The company reports 49,345,967 shares outstanding as of March 31, 2026 and a net tangible book value of $6.00 per share as of that date; dilution to new investors at the offering price is stated as $7.64 per share. Proceeds are intended to fund clinical trials, preclinical studies, manufacturing, R&D, capital expenditures, working capital and general corporate purposes.
Jade Biosciences, Inc. is offering shares of its common stock and pre-funded warrants in a registered offering under a Form S-3 shelf prospectus supplement dated June 3, 2026. The prospectus supplement describes primary sales of common stock and pre-funded warrants, with underwriting and customary lock-up arrangements.
The company reports 49,345,967 shares of common stock outstanding as of March 31, 2026, a reported net tangible book value of $296.5 million (approximately $6.00 per share) as of that date, and states $200 million of shares remain available under an existing Sales Agreement with Jefferies. The supplement discloses interim Phase 1 JADE101 data and plans for Phase 2/Phase 3 development, and includes customary risk factors, use-of-proceeds, dilution analysis, and tax discussion.
Jade Biosciences reported interim Phase 1 results for JADE101, its investigational anti‑APRIL antibody for IgA nephropathy. In 32 healthy volunteers given single subcutaneous doses from 175 mg to 1,400 mg, JADE101 showed a favorable safety profile, with only mild to moderate treatment‑emergent events and no severe adverse events or discontinuations.
A 700 mg dose produced prolonged IgA reductions of about 70% sustained at 12 weeks, with pharmacokinetic modeling suggesting this effect could be maintained using a 350 mg maintenance dose every 12 weeks. JADE101 demonstrated ultra‑high APRIL binding affinity, rapid and sustained free APRIL suppression, and an estimated half‑life of 24.2 days.
Jade has initiated JUNIPER, a Phase 2 open‑label IgA nephropathy trial in roughly 30 participants using a 700 mg induction dose followed by 350 mg maintenance every 8 or 12 weeks, with interim data anticipated in 2027. A registrational Phase 3 trial is planned for the first half of 2027, subject to FDA requirements. The company reports $311 million in cash, cash equivalents and investments as of March 31, 2026, which it expects to fund operations into the first half of 2028.
Jade Biosciences, Inc. is registering 39,542,339 shares of Common Stock for resale by selling stockholders under a shelf prospectus. The Resale Shares include October 2025 PIPE shares and pre-funded warrants, December 2025 PIPE shares, shares issued in connection with Pre-Merger Financing, and shares issuable upon conversion of Series A Preferred Stock.
The company states it will not receive proceeds from resale by the selling stockholders, but will receive nominal cash exercise prices if certain pre-funded warrants are exercised for cash. The registration satisfies contractual registration rights under April, October and December 2025 registration rights agreements.
Janus Henderson Group plc reported beneficial ownership of 3,105,669 shares of Jade Biosciences, Inc., equal to 6.3% of the common stock. The filing states Janus Henderson holds shared voting and dispositive power over those shares and identifies Janus Henderson Biotech Innovation Master Fund Ltd. as holding more than 5%. The filing was signed on 5/15/2026.
Jade Biosciences, Inc. filed a shelf resale registration covering 39,542,339 shares of common stock for resale by selling stockholders. The prospectus lists specific blocks from PIPE financings, pre-funded warrants and conversions of Series A Preferred Stock. The company will not receive proceeds from these resale transactions.
The filing states 49,316,287 shares outstanding as of March 15, 2026 for calculation purposes and discloses a last reported Nasdaq sale price of $25.26 per share (May 5, 2026). The registration satisfies contractual registration rights dated April, October and December 2025.
Jade Biosciences, Inc. filed a shelf registration to offer up to $600,000,000 of securities, including an at-the-market sales agreement to sell up to $200,000,000 of Common Stock through Jefferies LLC. The prospectus covers Common Stock, Preferred Stock, Debt Securities, Warrants and Units.
The prospectus describes an at-the-market program under a Sales Agreement dated May 7, 2026, Jefferies’ compensation up to 3.0% of gross proceeds, and incorporates risk factors and prior SEC filings by reference. Shares outstanding were 49,345,967 as of March 31, 2026.